Multimodality therapy is the standard of care with neoadjuvant systemic therapy for all women with locally advanced breast cancer with the advantage to induce tumor response, enable in vivo evaluation of its efficacy, improve surgical options because of the tumor response to therapy, facilitate local control through subsequent surgery and radiation therapy and improve overall survival.